199 Bay St, Suite 5300, Commerce Court West, Toronto, ON
Year called to bar: 1992 (QC); 2000 (ON)
Martin Langlois is a partner practising corporate and securities law, and a former co-head of the Mergers & Acquisitions and Private Equity Groups. He focuses on domestic and cross-border mergers & acquisitions (including leveraged buyouts), securities and corporate finance transactions, as well as corporate governance and other commercial matters. Martin has over 20 years of experience in a broad range of industries including technology, fintech, life sciences, financial services, mining and renewable energy. He is a member of the Management Committee and Co-Chair on the Women’s Initiatives Committee in the Toronto office. Martin is the former editor of the M&A Update. Martin is a member of the American Bar Association, the Canadian Venture Capital Association and the Association for Corporate Growth, and is a Fellow of the Intellectual Property Institute of Canada (IPIC). He has taught Advanced Company Law at the University of Western Ontario as a member of the adjunct faculty. Martin is fluent in French and English.
Vista Equity Partners (“Vista”) acquired all of the outstanding shares of Toronto-based DH Corp. (TSX: DH) (“D+H”), a leading provider of technology solutions to financial institutions globally, by way of a plan of arrangement for $25.50 per share in cash, for a total enterprise value of approximately $4.8 billion, including the assumption of D+H’s debt.
On May 25, 2016, ProMetic Life Sciences Inc. (ProMetic) completed its bought-deal public offering of common shares through a syndicate of underwriters led by RBC Capital Markets and Canaccord Genuity Corp., and that included Scotiabank, CIBC Capital Markets, National Bank Financial Inc., Paradigm Capital Inc. and Beacon Securities Ltd. (collectively, the Underwriters).
Merus Labs International Inc. closed a $60 million bought deal financing with a syndicate of investment dealers on April 30, 2015. Under the financing, Merus issued a total of 19,672,200 common shares at a price of $3.05 per share for gross proceeds of $60 million. The underwriters were granted a 30 day over-allotment option to increase the gross proceeds of the financing to $69 million
On July 31, 2015, NYX Gaming Group Limited (NYX or the Company) together with its wholly-owned subsidiary, NYX Digital Gaming (Canada) ULC (NYX Digital), completed the acquisition of the entire issued share capital of Amaya (Alberta) Inc., formerly Chartwell Technology Inc., and Cryptologic Limited from Amaya Inc. (Amaya) for an initial purchase price consisting of $110 million in cash, subject to customary working capital adjustments, and the issuance to Amaya of $40 million exchangeable preferred shares of NYX Digital. NYX also entered into a preferred supplier licensing agreement with a subsidiary of Amaya to provide certain casino gaming content to Amaya’s real-money casino offering, which will be integrated into the PokerStars and Full Tilt branded casino websites.
On May 6, 2015, ProMetic Life Sciences completed the bought deal public offering of common shares in the capital of the Corporation (the Offering) through a syndicate of underwriters led by Canaccord Genuity Corp., and which included RBC Dominion Securities Inc., Beacon Securities Limited, TD Securities Inc. and Paradigm Capital Inc. (collectively, the Underwriters). ProMetic issued 22,137,500 common shares of the Corporation (including the full exercise of the over-allotment option) in connection with the Offering at a price of $2.60 per share for aggregate gross proceeds of $57,557,500.